

# Study of RGL-270 Single Drug and Combined With Adebrelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors

NCT07348042

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Xian-Jun Yu
Enrollment	198 participants

## Key Eligibility Criteria

---

### Inclusion (14)

- Pre-screening period
- Subjects should understand and abide by the relevant research procedures, and voluntarily sign the prior informed consent form;
- Age 18-75 years old (including boundary value), gender is not limited;
- For malignant solid tumors confirmed by histology or cytology after radical resection, the subjects are allowed to complete standard adjuvant treatment, or no standard adjuvant treatment, or adjuvant treatment intolerance before receiving the first administration of this study;
- Willing to provide sufficient tumor tissue specimens and peripheral blood for genetic testing and new antigen analysis;
- ... and 9 more (see full listing online)

### Exclusion (30)

- Pre-screening period
- Have received immune cell or tumor vaccine treatment, including but not limited to tumor infiltration lymphocytes (TILs), chimeric antigen receptor T cells (CAR-T), T cell receptor chimeric T cells (TCR-T) and therapeutic tumor vaccines;
- Plan to inoculate live attenuated vaccine during the screening period or during the research period and within 90 days after the end of the research drug treatment (inactivated vaccine is allowed);
- Anyone who is evaluated by researchers as not suitable for immunotherapy;
- There is an autoimmune disease (except for hypothyroidism who need hormone replacement treatment caused by autoimmune thyroiditis);
- ... and 25 more (see full listing online)

## Locations (1 total)

---

Fudan University Shanghai Cancer Center, Shanghai, China